Palisade Bio, Inc.
Palisade Bio, Inc. (PALI) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PALI · as of Sep 30, 2025
Ownership Breakdown
12
Institutional Holders
▲ 1 vs Q2
$102,817
Total Inst. Value
▲ $45,273 vs Q2
173.58M
Shares Outstanding
freeFloat 98.49%
119,592
13F Shares Held
▲ 34,982 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PALI largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
TWO SIGMA SECURITIES, LLC biological products, (no diagnostic substances) | 29.4K | 39.34% | 39.34% | $25.28M | Nov 14, 2025 | ▲ 13.4K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 26.6K | 35.62% | 35.62% | $22.88M | Nov 12, 2025 | ▲ 1.9K |
UBS GROUP AG biological products, (no diagnostic substances) | 19.4K | 25.97% | 25.97% | $16.70M | Nov 13, 2025 | ▲ 19.1K |
XTX TOPCO LTD biological products, (no diagnostic substances) | 14.1K | 18.85% | 18.85% | $12.11M | Nov 14, 2025 | ▼ 13.3K |
NEWBRIDGE FINANCIAL SERVICES GROUP, INC. biological products, (no diagnostic substances) | 13.0K | 17.39% | 17.39% | $11.18M | Nov 13, 2025 | ▲ 2.5K |
MORGAN STANLEY biological products, (no diagnostic substances) | 8.6K | 11.53% | 11.53% | $7.41M | May 27, 2026 | ▲ 8.6K |
TOWER RESEARCH CAPITAL LLC (TRC) biological products, (no diagnostic substances) | 5.4K | 7.22% | 7.22% | $4.64M | Nov 14, 2025 | ▲ 829 |
CITIGROUP INC biological products, (no diagnostic substances) | 2.3K | 3.14% | 3.14% | $2.02M | Nov 10, 2025 | NEW |
ROCKEFELLER CAPITAL MANAGEMENT L.P. biological products, (no diagnostic substances) | 500 | 0.67% | 0.67% | $430,000 | Nov 14, 2025 | NEW |
FEDERATION DES CAISSES DESJARDINS DU QUEBEC biological products, (no diagnostic substances) | 100 | 0.13% | 0.13% | $86,000 | Nov 14, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
7
Increased
+46.4K shares2
New Positions
first time holders1
Decreased
−13.3K shares1
Sold Out
fully exitedNet shares change (top 50)
+33.1K
+46.4K / −13.3K
Net new holders
+7
2 new / 1 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PALI insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
6
Buy transactions
4
Sell transactions
1.50
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Jones Mitchell Lawrence Chief Medical Officer | Feb 12, 2026 | Sale | 1,989 | $1.75 | $3.5K | 13.3K | Form 4 ↗ |
Finley John David CEO, CFO | Feb 12, 2026 | Sale | 3,896 | $1.75 | $6.8K | 27.4K | Form 4 ↗ |
Jones Mitchell Lawrence Chief Medical Officer | Feb 9, 2026 | Award | 787,000 | — | — | 787.0K | Form 4 ↗ |
Finley John David CEO, CFO | Feb 9, 2026 | Award | 2,011,000 | — | — | 2.01M | Form 4 ↗ |
Williams Donald Allen director | Jan 16, 2026 | Purchase | 5,000 | $1.67 | $8.4K | 10.7K | Form 4 ↗ |
Williams Donald Allen director | Jan 9, 2026 | Purchase | 5,000 | $1.88 | $9.4K | 5.7K | Form 4 ↗ |
Williams Donald Allen director | Oct 6, 2025 | Award | 182,000 | — | — | 182.0K | Form 4 ↗ |
Wei Binxian director | Oct 6, 2025 | Award | 60,600 | — | — | 60.6K | Form 4 ↗ |
Chuang Emil director | Oct 6, 2025 | Award | 60,600 | — | — | 60.6K | Form 4 ↗ |
Williams Donald Allen director | Oct 6, 2025 | Award | 1,538,700 | — | — | 1.54M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Palisade Bio, Inc. (PALI) is primarily owned by institutional investors, who hold approximately 0.1% of total shares outstanding. Company insiders own approximately 1.51%, while retail and public investors account for the remaining 98.42%.
The largest institutional shareholder of Palisade Bio, Inc. is TWO SIGMA SECURITIES, LLC, holding approximately 29,406 shares — equal to 39.34% of outstanding shares — as of September 30, 2025.
A total of 12 institutional investors currently hold PALI stock, with a combined institutional value of approximately $102,817 as of the most recent 13F filing period.
Frequently asked questions
PALI ownershipPalisade Bio, Inc. (PALI) is primarily owned by institutional investors, who hold approximately 0.1% of shares. The largest shareholder is TWO SIGMA SECURITIES, LLC with a 39.34% stake. Company insiders hold 1.51%. Data sourced from SEC Form 13F as of September 30, 2025.